What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High‐Dose Methotrexate Use in Pediatric Malignancies
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31744 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Zachary L Taylor und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Methotrexate, Drug Monitoring, Antimetabolites, Antineoplastic, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BTG/SERB Pharmaceuticals.
Abstract (Originalsprache)
High‐dose methotrexate dosage and infusion durations differ across treatment protocols for pediatric leukemia, lymphoma, and osteosarcoma. Supportive care interventions are dependent on a patient's elimination of methotrexate (MTX). Therefore, it is important to establish the expected MTX elimination across protocols. Using modeling and simulation of real‐world data, we determined the expected MTX concentrations at common time points from the start of infusion (24, 36, 42, 48, 60, and 72 hours) and the time that each patient would reach a typical discharge threshold (0.4, 0.2, 0.15, and 0.10 µM). These data provide a reference for MTX concentrations for common pediatric protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Pediatrics, University of Cincinnati Collee of Medicine, Cincinnati, Ohio, USA.
- Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
- Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
- Division of Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
ORCID-Profile: Zachary L Taylor, Tamara P Miller, Ethan A Poweleit, Ashley Chavana, Austin L Brown, Melanie B Bernhardt, Eric S Schafer, Maureen M O'Brien, Sharon M Castellino, Laura B Ramsey
Förderung
- BTG/SERB Pharmaceuticals
Zitieren
APA
Taylor, Z. L., Miller, T. P., Board, S. G., Poweleit, E. A., Chavana, A., Weisnicht, A., Brown, A. L., Bernhardt, M. B., Schafer, E. S., O'Brien, M. M., Castellino, S. M., & Ramsey, L. B. (2025). What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High‐Dose Methotrexate Use in Pediatric Malignancies. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31744
Vancouver
Taylor ZL, Miller TP, Board SG, Poweleit EA, Chavana A, Weisnicht A, et al. What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High‐Dose Methotrexate Use in Pediatric Malignancies. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31744
BibTeX
@article{Taylor2025,
author = {Taylor, Zachary L and Miller, Tamara P and Board, Sarah G and Poweleit, Ethan A and Chavana, Ashley and Weisnicht, Allison and Brown, Austin L and Bernhardt, Melanie B and Schafer, Eric S and O'Brien, Maureen M and Castellino, Sharon M and Ramsey, Laura B},
title = {What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High‐Dose Methotrexate Use in Pediatric Malignancies},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31744}
}
EUVIMED